In the BioHarmony Drug Report Database
Xermelo (telotristat etiprate) is a small molecule pharmaceutical. Telotristat etiprate was first approved as Xermelo on 2017-02-28. It is used to treat diarrhea and malignant carcinoid syndrome in the USA. Xermelo’s patents are valid until 2031-02-27 (FDA).
Image (chem structure or protein)